Table 1 Demographics for the included participants
Variable | Molnupiravir (n = 253) | Usual Care (n = 324) | P-value |
|---|---|---|---|
Intensive sampling (%) | 38 (15%) | 42 (13%) | 0.557 |
Median number of viral load measurements per participant intensive group (range) | 8 (4,8) | 8 (4,8) | – |
Median number of viral load measurements per participant less-intensive group (range) | 3 (1,3) | 3 (1,3) | – |
Median number of spike antibody measurements per participant (range) | 3 (0,3) | 3 (0,3) | – |
Age years (sd) | 58 (10.1) | 58 (10.9) | 0.844 |
Female (%) | 139 (55%) | 212 (65%) | 0.0133 |
Ethnicity non-white (%) | 7 (3%) | 9 (3%) | >0.999 |
Fully vaccinated (≥3 doses) (%) | 240 (95%) | 314 (97%) | 0.3 |
Inhaled corticosteroids (%) | 56 (22%) | 70 (22%) | 0.959 |
Immune disease (%) | 23 (9%) | 21 (6%) | 0.311 |
Obesity (%) | 43 (17%) | 46 (14%) | 0.419 |
Any comorbidity (%) | 167 (66%) | 199 (61%) | 0.294 |
PANORAMIC primary outcome: Hospitalised or died (%) | 2 (0.79%) | 3 (0.93%) | >0.999 |
Mean days since symptom onset at baseline (sd) | 2.4 (0.78) | 2.5 (1.12) | 0.621 |
Mean viral load (log10(cp/mL)) at baseline (sd) | 7.4 (1.14) | 7.3 (1.04) | 0.334 |
Mean spike antibody (log10(U/mL)) at baseline (sd) | 3.3 (0.45) | 3.3 (0.44) | 0.91 |
Mean capillary CRP (mg/L) at baseline (sd) | 0.68 (0.65) | 0.65 (0.64) | 0.544 |
